| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Cellomics, Inc. |
| 635 William Pitt Way, Pittsburgh, PA 15238 * (412) 826-3600 |
| Business Description | The company is pioneering the emerging field of cellomics in an effort to extend the recent advances in genomics, the study of genes and proteomics, the study of proteins. |
|
Filing Information IPO has been | |||
| To Trade As | CLMX (NASNTL) | Industry | Service (SIC 8733) |
| Type of Stock Offered | Common Shares | Filing Date | 3/3/2000 |
| Domestic Shares Filed | 6,000,000 | Filing Range | $8.00 - $10.00 |
| Foreign Shares Filed | 0 | Offering Amount | $54,000,000 |
| Company Shares | 6,000,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Prudential Vector Healthcare | Lead Manager | (800) 546-1231 |
| Dain Rauscher Wessels | Co-manager | (612) 371-2818 |
| ING Baring Furman Selz | Co-manager | (212) 309-8200 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1997 | 12/31/1998 | 12/31/1999 | ||||
| Revenues | - | - | 0.395 | 2.273 | 4.490 | - | - |
| Income from Oper. | - | - | -2.425 | -3.509 | -9.975 | - | - |
| Net Income | - | - | -2.438 | -3.495 | -10.135 | - | - |
| E.P.S | - | - | -2.160 | -3.480 | -9.360 | - | - |
| Revenue Growth (%) | - | - | 475.44 | 97.536 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -7.15 | - | - | ||||
| Cash Flow - Inv. | -1.07 | - | - | ||||
| Cash Flow - Fin. | 8.90 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/1999 | Financial Ratios | ||||
| Total Assets | 5.86 | Current Assets | 3.47 | Current Ratio | 0.74 |
| Total Liab. | 21.59 | Current Liab. | 4.70 | Debt Ratio | 368.50% |
| Total Equity | -15.73 | Working Cap. | -1.22 | Debt to Equity Ratio | - |
| Cash | 1.34 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for technology research and product and services development, sale-up of sales and marketing, capital expenditures, working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Buchanan Ingersoll |
| Bank's Law Firm | Skadden, Arps, Slate, Meagher & Flom |
| Registrar/Transfer Agent | American Stock Transfer & Trust Co |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| InterWest Management VI LLC | 22.20 | |
| Axiom Venture Partners II Limited Partnership | 16.10 | |
| Delphi Management III, L.L.C. | 14.40 | |
| Vector Fund Management, L.P. | 8.40 | |
| Komasta Properties, Ltd. | 7.10 | |
| Carl Zeiss Golding Co., Inc. | 5.20 | |
| Alan S. Waggoner | 5.10 | |
| OBP Management II, L.P. | 4.80 | |
| OBP Management (Bermuda) II Limited Partnership | 2.90 | |
| Note: represents ownership of 5% or more prior to the offering. | ||